Zydus Lifesciences inches up on getting final approval from USFDA for Ketorolac Tromethamine Tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Zydus Lifesciences is currently trading at Rs. 413.20, up by 0.05 points or 0.01% from its previous closing of Rs. 413.15 on the BSE.
The scrip opened at Rs. 414.50 and has touched a high and low of Rs. 415.00 and Rs. 411.65 respectively.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 514.70 on 27-Oct-2021 and a 52 week low of Rs. 319.40 on 11-May-2022.
Last one week high and low of the scrip stood at Rs. 419.30 and Rs. 408.55 respectively. The current market cap of the company is Rs. 41915.37 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 15.53% and 9.49% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Ketorolac Tromethamine Tablets USP, 10 mg (USRLD: Toradol). Ketorolac Tromethamine Tablets are indicated to relieve moderately severe pain, usually after surgery. The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India.
Ketorolac Tromethamine Tablets had annual sales of $ 17mn in the United States. The group now has 328 approvals and has so far filed over 428 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
